DAX ®12.430,88+0,85%TecDAX ®2.816,83-0,28%Dow Jones26.743,50+0,32%NASDAQ 1007.531,07-0,50%
finanztreff.de

DGAP-Adhoc: Epigenomics AG: Centers for Medicare & Medicaid Services publish preliminary rate of $192 for Epigenomics' colorectal cancer screening test Epi proColon(R)

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 2 min. | Text vorlesen Stop Pause Fortsetzen
DJ DGAP-Adhoc: Epigenomics AG: Centers for Medicare & Medicaid Services publish preliminary rate of $192 for Epigenomics' colorectal cancer screening test Epi proColon(R)



DGAP-Ad-hoc: Epigenomics AG / Key word(s): Miscellaneous
Epigenomics AG: Centers for Medicare & Medicaid Services publish preliminary
rate of $192 for Epigenomics' colorectal cancer screening test Epi
proColon(R)

09-Jun-2018 / 12:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of Inside Information according to Article 17 MAR

*Centers for Medicare & Medicaid Services publish preliminary rate of $192
for Epigenomics' colorectal cancer screening test Epi proColon(R)*

_June 9, 2018 __-_ Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX:
EPGNY), announced today that the Centers for Medicare & Medicaid Services
(CMS) published a preliminary rate of $192 per Epi proColon test. Epi
proColon is the first and only FDA-approved blood-based test for colorectal
cancer screening. A press release with further details will be published on
Monday, June 11, 2018.

Contact:
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829
Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail:
ir@epigenomics.com

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any expected
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events or
otherwise.

09-Jun-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart,
Tradegate Exchange

End of Announcement DGAP News Service

693993 09-Jun-2018 CET/CEST



(END) Dow Jones Newswires

June 09, 2018 06:20 ET ( 10:20 GMT)
Werbung

Das könnte Sie auch interessieren

Im Artikel erwähnt...

EPIGENOMICS AG NA O.N.
EPIGENOMICS AG NA O.N. - Performance (3 Monate) 2,22 ±0,00%
EUR ±0,00
Porträt - Chart - Kennzahlen - Firmenprofil
Nachrichten
10.09. DGAP-DD: Epigenomics AG deutsch
10.09. DGAP-DD: Epigenomics AG english
10.09. DGAP-DD: Epigenomics AG deutsch
Werbung
Werbung

News-Suche

Suchbegriff:
Werbung
Werbung

Werbung
Börse Stuttgartschliessen
Börse Stuttgart

Gewinnen Sie pures Gold!

Unter allen Teilnehmern an der Anlegerumfrage verlost der Börse Stuttgart Anlegerclub Gold im Gesamtwert von über 1000 Euro.

Jetzt kostenlos anmelden und mitmachen!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 39 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen
schliessen